Adaptimmune Therapeutics plc (ADAPY)
OTCMKTS · Delayed Price · Currency is USD
0.0261
-0.0039 (-13.00%)
Jul 31, 2026, 11:52 AM EST

Adaptimmune Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
25.9591.14143.99108.03149.95
Short-Term Investments
-60.472.9596.57219.63
Cash & Short-Term Investments
25.95151.61146.94204.61369.58
Cash Growth
-82.88%3.18%-28.18%-44.64%0.37%
Accounts Receivable
6.991.450.827.440.75
Other Receivables
3.4812.9346.130.1630.77
Total Trade Receivables
10.4714.3846.9237.631.53
Inventory
-7.32---
Other Current Assets
8.8913.7314.114.0117.13
Total Current Assets
45.31187.04207.96256.22418.23
Net Property, Plant & Equipment
16.2948.7969.5969.9651.35
Other Intangible Assets
0.028.525.655.713.42
Other Long-Term Assets
1.732.073.033.072.22
Total Assets
63.36246.42286.22334.95485.22
Accounts Payable
16.6140.9838.4335.9738.02
Current Portion of Leases
4.934.725.392.82.64
Unearned Revenue
-12.328.9723.5222.2
Other Current Liabilities
0.76.85-3.23-
Total Current Liabilities
22.2464.8572.865.5262.86
Long-Term Debt
-50.24---
Long-Term Leases
9.1519.3319.9320.5724.42
Other Long-Term Liabilities
-98.96150.46162.19177.9
Total Long-Term Liabilities
9.15168.53170.4182.76202.32
Total Liabilities
31.39233.38243.2248.28265.18
Common Stock
2.162.091.871.41.34
Additional Paid-in Capital
961959.23930.2869.03856.22
Accumulated Other Comprehensive Income
-16.74-9.78-11.5-8.99-18.06
Retained Earnings
-914.45-938.5-877.55-774.77-619.46
Shareholders' Equity
31.9713.0443.0386.67220.05
Total Liabilities & Equity
63.36246.42286.22334.95485.22
Total Debt
14.0874.2925.3323.3727.06
Net Cash (Debt)
11.8777.32121.61181.23342.52
Net Cash Growth
-84.65%-36.42%-32.90%-47.09%-0.58%
Net Cash Per Share
0.010.040.100.190.37
Book Value
31.9713.0443.0386.67220.05
Book Value Per Share
0.020.010.040.090.24
Tangible Book Value
31.954.5237.3880.97206.62
Tangible Book Value Per Share
0.020.000.030.080.22